- ISIN
- US6979471090
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 16, 2024
Highlights
- Market Cap
- $1.34B
- Enterprise Value
- $1.28B
- EPS (TTM)
- -$3.75
- EBITDA (TTM)
- -$14.75M
- Year Range
- $20.35 - $151.18
- Target Price
- $203.92
- ROA (TTM)
- -70.04%
- ROE (TTM)
- -149.07%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PVLA Performance Chart
Palvella Therapeutics, Inc (PVLA) is up 13.4% since the beginning of the year. At $119 per share, PVLA is trading 21.5% below its 52-week high of $151.
Loading charts...
Returns By Period
Palvella Therapeutics, Inc (PVLA) has returned 13.38% so far this year and 426.53% over the past 12 months.
Palvella Therapeutics, Inc
- 1D
- -0.13%
- 1M
- 4.11%
- YTD
- 13.38%
- 6M
- 18.36%
- 1Y
- 426.53%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
PVLA Monthly Returns History
Based on dividend-adjusted daily data since Dec 16, 2024, PVLA's average daily return is +0.71%, while the average monthly return is +15.49%. At this rate, an investment would double in approximately 0.4 years.
Historically, 63% of months were positive and 37% were negative. The best month was Feb 2026 with a return of +76.1%, while the worst month was Jan 2026 at -26.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.
On a daily basis, PVLA closed higher 52% of trading days. The best single day was Feb 24, 2026 with a return of +37.1%, while the worst single day was Apr 7, 2025 at -16.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.73% | 76.06% | -7.68% | 2.94% | -7.68% | 0.19% | 13.38% | ||||||
| 2025 | 8.33% | 49.00% | 44.50% | -13.25% | -0.62% | -6.59% | 62.29% | 48.03% | 15.77% | 27.36% | 28.74% | 1.83% | 772.25% |
| 2024 | -8.27% | -8.27% |
Benchmark Metrics
Palvella Therapeutics, Inc has an annualized alpha of 413.10%, beta of 1.07, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 16, 2024.
- This stock captured 471.07% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1462.35%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 413.10%
- Beta
- 1.07
- R²
- 0.05
- Upside Capture
- 471.07%
- Downside Capture
- -1,462.35%
Return for Risk
Risk / Return Rank
PVLA ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PVLA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.54 | ||
| Sortino ratioReturn per unit of downside risk | +2.03 | ||
| Omega ratioGain probability vs. loss probability | 1.54 | 1.32 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 13.82 | 2.46 | +11.37 |
| Martin ratioReturn relative to average drawdown | 31.14 | 10.92 | +20.23 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Palvella Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Palvella Therapeutics, Inc was 31.48%, occurring on Apr 10, 2025. Recovery took 66 trading sessions.
The current Palvella Therapeutics, Inc drawdown is 19.99%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -31.48%Apr 2025 | 28d | 3mo 8d | 4mo 6dMar 2025 - Jul 2025 |
2026 bear market2026 | -31.11%Jun 2026 | 3mo 13d | — | 3mo 27dFeb 2026 - now |
2026 bear market2026 | -29.93%Feb 2026 | 1mo 14d | 19d | 2mo 3dDec 2025 - Feb 2026 |
2025 correction2025 | -15.35%Jan 2025 | 17d | 12d | 29dJan 2025 - Feb 2025 |
2025 correction2025 | -13.44%Dec 2025 | 14d | 7d | 21dDec 2025 - Dec 2025 |
Drawdown Indicators
| PVLA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -31.48% | -56.78% | +25.30% |
Max Drawdown (1Y)Largest decline over 1 year | -31.11% | -9.10% | -22.01% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -19.99% | -3.21% | -16.78% |
Average DrawdownAverage peak-to-trough decline | -11.16% | -10.71% | -0.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.79% | 2.04% | +11.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Palvella Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Palvella Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PVLA in comparison with other companies in the Biotechnology industry. Currently, PVLA has a P/B value of 47.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PVLA
Add Palvella Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PVLA